Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease

 

 Buy Article Permissions and Reprints

Abstract

Current guidelines recommend that patients with cancer be assessed for venous thromboembolism (VTE) risk at the time of chemotherapy initiation and periodically thereafter. Rates of VTE vary substantially among cancer patients. Multiple clinical factors contribute to VTE risk, including the primary site of cancer, extent of disease, interventions including major surgery, hospitalization, and systemic therapy. However, risk of VTE cannot reliably be predicted based on a single risk factor or biomarker. Within the last decade, risk assessment scores have been developed in cancer patients to more reliably predict thromboembolic events. This review provides an overview of evidence supporting the use of such tools for both primary and recurrent cancer-associated VTE. Potential applications of risk assessment tools as well as current knowledge gaps are outlined.

• References

• 1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
  CrossrefPubMedGoogle Scholar
• 2 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
  CrossrefPubMedGoogle Scholar
• 3 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
  CrossrefPubMedGoogle Scholar
• 4 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
  CrossrefPubMedGoogle Scholar
• 5 Piazza G. Venous thromboembolism and cancer. Circulation 2013; 128 (24) 2614-2618
  CrossrefPubMedGoogle Scholar
• 6 Otten HM, Mathijssen J, ten Cate H. , et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164 (02) 190-194
  CrossrefPubMedGoogle Scholar
• 7 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
  CrossrefPubMedGoogle Scholar
• 8 Wells PS, Anderson DR, Rodger M. , et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349 (13) 1227-1235
  CrossrefPubMedGoogle Scholar
• 9 Palareti G, Cosmi B, Legnani C. , et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
  CrossrefPubMedGoogle Scholar
• 10 Verhovsek M, Douketis JD, Yi Q. , et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149 (07) 481-490 , W94
  CrossrefPubMedGoogle Scholar
• 11 Vandy FC, Stabler C, Eliassen AM. , et al. Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2013; 1 (02) 117-1125
  PubMedGoogle Scholar
• 12 Agnelli G, Gussoni G, Bianchini C. , et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
  CrossrefPubMedGoogle Scholar
• 13 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012; 7 (03) 291-292
  CrossrefPubMedGoogle Scholar
• 14 Barni S, Labianca R, Agnelli G. , et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179
  CrossrefPubMedGoogle Scholar
• 15 Zangari M, Anaissie E, Barlogie B. , et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98 (05) 1614-1615
  CrossrefPubMedGoogle Scholar
• 16 IMWG Guidelines for the Prevention of Thalidomide and Lenalidomide Associated Thrombosis in Myeloma. Available at http://imwg.myeloma.org Accessed March 2, 2016
  PubMedGoogle Scholar
• 17 Sousou T, Khorana AA. Cancer patients and awareness of venous thromboembolism. Cancer Invest 2010; 28 (01) 44-45
  CrossrefPubMedGoogle Scholar
• 18 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
  CrossrefPubMedGoogle Scholar
• 19 Lustig D, Wells P, Rodrigues R. , et al. Implementing a computerized care process management system to determine the feasibility of utilizing, and concomitantly validating, a prediction tool for the risk of venous thromboembolism in cancer patients. Blood 2013; 122: 1688
  PubMedGoogle Scholar
• 20 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 (17) 2405-2409
  CrossrefPubMedGoogle Scholar
• 21 Di Nisio M, Lee AY, Carrier M, Liebman HA, Khorana AA. ; Subcommittee on Haemostasis and Malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13 (05) 880-883
  CrossrefPubMedGoogle Scholar
• 22 Khorana AA, Rubens D, Francis CW. Screening high-risk cancer patients for VTE: a prospective observational study. Thromb Res 2014; 134 (06) 1205-1207
  CrossrefPubMedGoogle Scholar
• 23 Khorana AA, Francis CW, Kuderer N. , et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Blood 2015; 126: 427
  CrossrefPubMedGoogle Scholar
• 24 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 9 (07) e1001275
  CrossrefPubMedGoogle Scholar
• 25 Agnelli G, George DJ, Kakkar AK. , et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
  CrossrefPubMedGoogle Scholar
• 26 George D, Agnelli G, Fisher W. , et al. Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. 2011 ASH Annual Meeting Abstracts (120) 21. 206
  PubMedGoogle Scholar
• 27 Lyman GH, Bohlke K, Khorana AA. , et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 2015; 33 (06) 654-656
  CrossrefPubMedGoogle Scholar
• 28 Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 81-91
  CrossrefPubMedGoogle Scholar
• 29 Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A validated risk score for venous thromboembolism is predictive of cancer progression and mortality. Oncologist 2016; 21 (07) 861-867
  CrossrefPubMedGoogle Scholar
• 30 Posch F, Riedl J, Reitter EM. , et al. Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A multi-state model. Thromb Haemost 2016; 115 (04) 817-826
  Article in Thieme ConnectPubMedGoogle Scholar
• 31 Sohal DP, Shrotriya S, Glass KT. , et al. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Cancer 2015; 121 (11) 1779-1784
  CrossrefPubMedGoogle Scholar
• 32 Sohal D, Kuderer NM, Shepherd FA. , et al. Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: results from a global prospective study. J Clin Oncol 2014; 32 (Suppl. 03) abstract 532
  PubMedGoogle Scholar
• 33 Kuderer NM, Poniewierski MS, Culakova E. , et al. Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy. J Clin Oncol 2016; 34 (Suppl. 03) abstract 9078
  PubMedGoogle Scholar
• 34 Alikhan R, Cohen AT, Combe S. , et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14 (04) 341-346
  CrossrefPubMedGoogle Scholar
• 35 Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014; 127 (01) 82-6 .e1
  CrossrefPubMedGoogle Scholar
• 36 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 304-312
  PubMedGoogle Scholar
• 37 Arcelus JI, Candocia S, Traverso CI, Fabrega F, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 313-318
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 Zhou HX, Peng LQ, Yan Y. , et al. Validation of the Caprini risk assessment model in Chinese hospitalized patients with venous thromboembolism. Thromb Res 2012; 130 (05) 735-740
  CrossrefPubMedGoogle Scholar
• 39 Ruch JM, Hu HM, Bahl V, Sood SL. Impact of Venous Thromboembolism (VTE) Prophylaxis and Risk Stratification with the Caprini Model in Hospitalized Patients with Cancer. ASH Annual Meeting Abstracts 2012; 120: 364
  PubMedGoogle Scholar
• 40 Barbar S, Noventa F, Rossetto V. , et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
  CrossrefPubMedGoogle Scholar
• 41 Spyropoulos AC, Anderson Jr FA, Fitzgerald G. , et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140 (03) 706-714
  CrossrefPubMedGoogle Scholar
• 42 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  CrossrefPubMedGoogle Scholar
• 43 Angelini DG, Wietzke J. , et al. Defining the Risk:Benefit Ratio of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Cancer Patients. ASH Annual Meeting Abstracts 2015; 23 (126) 627
  PubMedGoogle Scholar
• 44 Patell R, Rybicki LA, Elson P. , et al. Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool. J Clin Oncol 2016; 34 (Suppl):abstract 6598
  PubMedGoogle Scholar
• 45 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
  CrossrefPubMedGoogle Scholar
• 46 Lee AY, Bauersachs R, Janas MS. , et al; CATCH Investigators. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284
  CrossrefPubMedGoogle Scholar
• 47 Lee AY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
  CrossrefPubMedGoogle Scholar
• 48 Louzada ML, Carrier M, Lazo-Langner A. , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
  CrossrefPubMedGoogle Scholar
• 49 den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 2013; 11 (05) 998-1000
  CrossrefPubMedGoogle Scholar
• 50 Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Support Care Cancer 2013; 21 (08) 2309-2313
  CrossrefPubMedGoogle Scholar
• 51 Khorana AA, Bauersachs R, Kamphuisen PW. , et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. J Clin Oncol 2015; 33: 9621 (Meeting Abstracts)
  PubMedGoogle Scholar
• 52 Khorana AA, Kamphuisen PW, Meyer G. , et al. Tissue factor (TF) as predictor of recurrent venous thromboembolism (VTE): risk factor and biomarker analysis from the catch trial of treatment of cancer associated VTE with tinzaparin or warfarin. J Thromb Haemost 2015; 13: 1-997
  PubMedGoogle Scholar
• 53 Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24 (03) 484-490
  CrossrefPubMedGoogle Scholar
• 54 Kearney JC, Rossi S, Glinert K, Henry DH. Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model. Blood 2009; 114: 2503
  PubMedGoogle Scholar
• 55 Price LH, Nguyen MB, Picozzi VJ, Kozarek RA. Portal vein thrombosis in pancreatic cancer: natural history, risk factors and implications for patient management. Gastrointestinal Cancer Symposium; 2010 ; abstract number 143
  PubMedGoogle Scholar
• 56 Ay C, Dunkler D, Marosi C. , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
  CrossrefPubMedGoogle Scholar
• 57 Moore RA, Adel N, Riedel E. , et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
  CrossrefPubMedGoogle Scholar
• 58 Mandala M, Clerici M, Corradino I. , et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol 2012; 23 (06) 1416-1421
  CrossrefPubMedGoogle Scholar
• 59 Sharma D, Kim SY, Henry D. Assessing a prognostic model for predicting VTE occurrence in cancer patients. J Clin Oncol 2012; 30 (Suppl):abstract 1577
  CrossrefPubMedGoogle Scholar
• 60 Moinat CH, Périard D, Grueber A. , et al. Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. J Oncol 2014; 2014: 743181
  PubMedGoogle Scholar
• 61 Lustig DB, Rodriguez R, Wells PS. Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thromb Res 2015; 136 (06) 1099-1102
  CrossrefPubMedGoogle Scholar
• 62 Srikanthan A, Tran B, Beausoleil M. , et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 2015; 33 (06) 582-587
  CrossrefPubMedGoogle Scholar
• 63 Santi RM, Ceccarelli M, Catania G. , et al. Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non Hodgkin lymphoma (NHL). a pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Blood 2015; 126: 3934
  PubMedGoogle Scholar